




Section: 25. Medicines acting on the respiratory tract > 25.1. Antiasthmatic and medicines for chronic obstructive pulmonary disease

ATC codes: **R03AK07**

Indication	Asthma <b>ICD11 code: CA23</b>
INN	Budesonide + formoterol
Medicine type	Chemical agent
List type	Core
Formulations	Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose ; 200 µg + 6 µg per dose
EML status history	First added in 2017 ( <b>TRS 1006</b> ) Changed in 2021 ( <b>TRS 1035</b> )
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	budesonide + salmeterol (ATC codes: R03AK12) beclometasone + formoterol (ATC codes: R03AK08) mometasone + formoterol (ATC codes: R03AK09) fluticasone + formoterol (ATC codes: R03AK11) fluticasone furoate + vilanterol (ATC codes: R03AK10)
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Budesonide + formoterol</a> 
DrugBank	<a href="#">Budesonide</a>  , <a href="#">Formoterol</a> 

## Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended the following be specified as therapeutic alternatives under the square box listing for budesonide + formoterol for treatment of asthma on the EML: beclometasone + formoterol, budesonide + salmeterol, fluticasone + formoterol, fluticasone furoate + vilanterol, and mometasone + formoterol.

